Clinical Trials
21 trialsPanitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Academic and Community Cancer Research United
STRATEGIC-1
GERCOR - Multidisciplinary Oncology Cooperative Group
A Phase 2 Basket Trial in Which Patients With Advanced Solid Tumors Carrying the KRAS G12C mUtation Receive Treatment With a Combination of Sotorasib and Panitumumab
Korea University Anam Hospital
FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer
Criterium, Inc.
PACER
National Cancer Institute, Naples
REPAN
King Abdullah Medical City
BEYOND
Grupo Espanol Multidisciplinario del Cancer Digestivo
A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma
Benaroya Research Institute
PANDA
Gruppo Oncologico del Nord-Ovest
Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer
Dr. Reddy's Laboratories Limited
FOxTROT
University of Birmingham
AVOCETTE
University Hospital, Caen
Valentino
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
NEO-RIT
WiSP Wissenschaftlicher Service Pharma GmbH
Capecitabine, Panitumumab, and Radiation Therapy With or Without Irinotecan Hydrochloride in Treating Patients Undergoing Surgery for Localized Rectal Cancer
National Cancer Institute (NCI)
Simvastatin and Panitumumab in Treating Patients With Advanced or Metastatic Colorectal Cancer
National Cancer Institute (NCI)
PROVE
WiSP Wissenschaftlicher Service Pharma GmbH
Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients
Ludwig-Maximilians - University of Munich
ACTIVE
Associacio catalana per a la recerca oncologica i les seves implicacions sanitaries i socials
PASCE
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical Cancer
National Cancer Institute (NCI)